AMG National Trust Bank Increases Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

AMG National Trust Bank boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,738 shares of the company’s stock after purchasing an additional 4,073 shares during the period. AMG National Trust Bank’s holdings in Elanco Animal Health were worth $1,965,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. 180 Wealth Advisors LLC raised its stake in Elanco Animal Health by 3.6% during the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after purchasing an additional 893 shares during the period. HBK Sorce Advisory LLC raised its position in shares of Elanco Animal Health by 9.4% during the second quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after buying an additional 1,107 shares during the last quarter. Atomi Financial Group Inc. lifted its holdings in shares of Elanco Animal Health by 11.1% in the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock worth $177,000 after buying an additional 1,221 shares in the last quarter. Keene & Associates Inc. boosted its position in shares of Elanco Animal Health by 5.7% during the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock worth $337,000 after acquiring an additional 1,240 shares during the last quarter. Finally, Resonant Capital Advisors LLC grew its stake in Elanco Animal Health by 5.0% during the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company’s stock valued at $394,000 after acquiring an additional 1,306 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Buying and Selling at Elanco Animal Health

In other news, Director Michael J. Harrington acquired 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the completion of the purchase, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 4.51 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $13.45 on Tuesday. The firm has a market capitalization of $6.65 billion, a price-to-earnings ratio of 33.63, a PEG ratio of 1.46 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The business has a 50 day simple moving average of $13.79 and a 200-day simple moving average of $14.77. Elanco Animal Health Incorporated has a 1 year low of $11.40 and a 1 year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the company earned $0.18 earnings per share. Elanco Animal Health’s revenue was down 3.6% on a year-over-year basis. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Barclays raised their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $17.14.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.